Evidence map›Paper›PMID 39219484›Full record

ArticleSubstance use & addiction journal2025

Racial Differences in Medications for Opioid Use Disorder Initiation in a Carceral Setting.

Justin Berk, Jessica Brar, Ariel Hoadley, Rosemarie Martin

Abstract read
In one paragraph

Article in Substance use & addiction journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Observational
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Justin BerkDepartment of Medicine, Alpert Medical School, Brown University, Providence, RI, USA.ORCID 0000-0002-2865-7464
Jessica BrarDepartment of Medicine, Alpert Medical School, Brown University, Providence, RI, USA.
Ariel HoadleyDepartment of Social and Behavioral Sciences, Temple College of Public Health, Philadelphia, PA, USA.
Rosemarie MartinDepartment of Behavioral and Social Sciences, Center for Alcohol and Addiction Studies, Brown School of Public Health, RI, USA.

Funding

Using Implementation Interventions and Peer Recovery Support to Improve Opioid Treatment Outcomes in Community SupervisionU01DA050442 · NIDA · BROWN UNIVERSITY · PI BRINKLEY-RUBINSTEIN, LAUREN, MARTIN, ROSEMARIE A · 2019 to 2024
$12.6M
Injectable Extended-Release Buprenorphine (XR-B) in a Correctional Setting: A Pilot Randomized Controlled TrialK23DA055695 · NIDA · RHODE ISLAND HOSPITAL · PI Justin Berk · 2022 to 2026
$1.0M
NIDA NIH HHS K23 DA055695NIDA NIH HHS U01 DA050442
6 · The paper itself

Abstract

backgroundThe opioid overdose crisis significantly affects marginalized communities, with people of color experiencing higher rates of overdose and barriers to treatment. The syndemic of opioid use disorder and mass incarceration exacerbates racial health disparities. Some carceral facilities offer medication for addiction treatment, though no significant research explores differences in type of treatment uptake by race in these settings. This study focuses on the racial differences in medications for opioid use disorder (MOUD) preferences among incarcerated individuals.

methodsA retrospective cohort study was conducted at the Rhode Island Department of Corrections (RIDOC), examining MOUD-type preferences (buprenorphine or methadone) among incarcerated individuals. The study utilized RIDOC electronic medical records from January 1, 2017 to December 31, 2022, involving 3533 unique incarceration events. Participants were categorized by race (White vs non-White) and MOUD status (new initiation vs community continuation), with logistic regression models.

resultsThe study found no direct racial disparity in preferences for MOUD type. However, an interaction between race and MOUD initiation status significantly influenced MOUD-type preference. Among those initiating MOUD during incarceration, non-White individuals were more likely to choose buprenorphine compared to their White counterparts.

conclusionsThis research provides new insights into the intersection of race, incarceration, and MOUD preferences. While direct racial disparities in MOUD type were not observed, the analysis uncovered a notable interaction effect: race influences the relationship between MOUD initiation status and the selected MOUD treatment during incarceration. Specifically, data demonstrate that the likelihood of choosing buprenorphine varies significantly based on both racial background and whether the treatment was initiated during incarceration or in the community. Further research is needed in different geographic settings to understand the broader implications to help guide equitable healthcare delivery in jails and prisons.

Indexed as

BuprenorphineMethadoneOpiate Substitution TreatmentOpioid-Related DisordersPrisonersAdultAnalgesics, OpioidFemaleHealthcare DisparitiesHumansMaleMiddle AgedPrisonsRetrospective StudiesRhode IslandWhiteAnalgesics, OpioidBuprenorphineMethadoneaddictionbuprenorphinecriminal justicemethadoneOUDracial disparities

Identifiers

PMID39219484
PMCPMC11979573

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.